Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational long-term safety follow-up of infliximab in moderate to severe COPD
2006-003431-78Phase 3Completed
- Sponsor
- Janssen Biotech
- Start
- Sep 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infliximab in chronic obstructive pulmonary disease (COPD), sponsored by Janssen Biotech. Primary endpoints: Incidence of malignancy and Mortality. Started Sep 2006; status: completed.
02
Drugs
infliximab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-003431-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003431-78.